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Abstract
Background
Faster identification of bacterial isolates from blood cultures can enable earlier clinical inter-
vention for patients with sepsis. We evaluated the clinical impact of direct identification of
micro-organisms from positive blood cultures using MALDI-ToF.
Method
Positive blood cultures with organisms seen on Gram stain were included over a four week
period. For each patient case, comparison was made between the clinical advice given on
day one with only a Gram stain result, and the follow up advice given on day two with the
benefit of organism identification. Culture results were then compared with direct MALDI-
ToF identification.
Results
For 73 of 115 cases (63.5%), direct organism identification was obtained by MALDI-ToF. Of
those 73, 70 (95.5%) had a result concordant with that of the plate culture. In 28 of the 115
cases (24.3%) direct MALDI-ToF identification on day one would have had a clear clinical
benefit. In 11 cases it would have helped to identify the potential source of bacteraemia. In
11 cases it would have indicated a different antibiotic regimen on day one, with five patients
receiving appropriate antibiotics 24 hours earlier. For 14 cases the blood culture isolate
could have been designated as unlikely to be clinically significant.
Conclusion
We have demonstrated that organism identification on day one of blood culture positivity
can have a direct clinical impact. Faster identification using MALDI-ToF assists the clinician
in assessing the significance of a blood culture isolate on day one. It can allow earlier
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appropriate choice of antimicrobial agent, even in the absence of susceptibility testing, and
help narrow down the potential source of infection providing a focus for further investigation
in a more timely way than conventional techniques alone.
Introduction
Bacteraemia in the acutely unwell patient carries a significant morbidity and mortality. Prompt
treatment with appropriate antimicrobial agents, along with supportive care, improves patient
outcome [1]. However, conventional culture techniques are time-consuming with results often
only available 48 hours after the patient has presented with an acute illness. Prompt identifica-
tion of microorganisms grown in blood cultures has the potential to enable earlier targeted
clinical intervention for patients with sepsis. Matrix assisted laser desorption ionization time-
of-flight (MALDI ToF) mass spectrometry has been established as a rapid method for identifi-
cation of cultured bacterial isolates [2]. Use of this technology has been extended to identifica-
tion of bacteria directly from positive blood culture broths with some success [3–6]. Rates for
correct identification to species level are reported as between 71.2% [7] and 85.5% [4], with
MALDI-ToF consistently demonstrating greater success in identification of Gram negative
organisms when compared with Gram positive organisms [3,4]. Lagace´-Weins et al [8] report
that using MALDI-ToF on positive blood culture broths significantly reduces time to organism
identification with a mean time reduction of 34.3 hours. Similar results have been reported by
Schneiderhan et al [9] who report a mean reduction in time to organism identification of 58.7
hours, although the authors acknowledge this is dependent upon workflow and continuous
blood culture incubation and processing. However, it is unclear the extent to which earlier spe-
cies identification directly from blood culture broths can impact on clinical decision making.
Clerc et al [10] report a series of 202 cases of Gram negative bacteraemia with 35.1% of cases
having changes made to antimicrobial therapy as a result of MALDI-ToF identification, as
opposed to 20.8% of cases with Gram stain result only. Similarly, Vlek et al [11] describe an
increase in the proportion of patients on adequate antimicrobial therapy within 24 hours of a
positive blood culture when using MALDI-ToF identification directly from broths. However,
clinical management encompasses more than choice of antimicrobial agent alone.
We assess the impact of direct MALDI-ToF identification of blood culture isolates on a
range of clinical decisions including source investigation, infection control management, and
antimicrobial therapy choices.
Materials and Methods
Blood culture
Blood was cultured in the Public Health Laboratory Birmingham using the bioMe´rieux BacT/
ALERT1 3D system. Blood cultures used in this study were received in aerobic and anaerobic
bottles containing no charcoal which are designed to take up to 10ml of blood. Within labora-
tory working hours (7am to 7pm), bottles were removed from the incubator when microbial
growth in the culture bottles was indicated. A Gram stain was performed directly on an aliquot
of culture. Based on the morphology of the organisms seen, culture plates were inoculated,
incubated for 18-48hrs and examined daily for microbial growth. Identification of cultured
isolates was performed using the Bruker MALDI Biotyper system for MALDI-ToF or BioMer-
ieux VITEK12 ID system.
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Direct MALDI-ToF
Briefly, 1 ml of each positive blood culture (with organisms seen on Gram stain) was mixed
with 200 μl of 10% sodium dodecyl sulphate (SDS) solution, briefly vortex mixed and incu-
bated at room temperature for 5 min then centrifuged for 1 min at 13,000 g. The supernatant
was removed and each pellet re-suspended in 1 ml mass spectrometry grade water then centri-
fuged for 1 min at 13,000 g. Supernatant was removed and each sample was re-suspended in
300 μl mass spectrometry grade water and 900 μl 100% ethanol followed by centrifugation for
2 minutes at 13,000 g. The supernatant was then removed and each sample centrifuged again
for 2 minutes at 13,000 g. Residual ethanol was then removed and the pellets dried for 10 min-
utes at room temperature. Ethanol/formic acid extraction was then carried out. One microliter
of each extracted supernatant was spotted in duplicate onto MALDI-ToF target plates, dried
and 1 μl α-Cyano-4-hydroxycinnamic acid (HCCA) matrix solution was added and dried.
Genus and species identification was then obtained using a Bruker MALDI Biotyper system.
Clinical data collection
Clinical data was collected over four weeks in December 2013. All positive blood cultures with
organisms seen on Gram stain from patients over 18 years of age were included, and each indi-
vidual patient case examined. For each case, the following data were collected on day one with
the Gram stain result, and again on day two when the organism identification was known:
likely clinical significance of the positive blood culture isolate; likely source or focus of infec-
tion; recommended clinical or laboratory investigations; advice regarding antimicrobial che-
motherapy; recommended infection control interventions. A comparison was made between
advice given on day one with only a Gram stain result, and the follow up advice given on day
two with the benefit of organism identification. Changes in clinical advice of the above catego-
ries were recorded.
Comparison of culture identification with direct MALDI-ToF identification
Direct MALDI-ToF identification was performed in parallel with conventional culture for all
included cases. Identification generated from the direct MALDI-ToF method was not dis-
closed to the medical microbiologist until after culture results were available to avoid contami-
nation of clinical decision making with a non-validated result. In order to correctly attribute
any patient management changes to an earlier organism identification it was necessary to
establish that the direct MALDI-ToF method would correctly provide that identification. Day
two conventional culture identification results were therefore compared with the results gener-
ated through direct MALDI-ToF identification from blood culture bottles. Cases where MAL-
DI-ToF gave an organism identification were considered as having the potential to change
clinical management on day one. All cases were reviewed by an independent second assessor.
Incidents of disagreement between the assessors were discussed further until consensus was
reached.
This project was approved by internal ethical review by the Public Health England Research
Support and Governance Office. Consent from patients was not sought as the study was a
comparison of two methods to establish efficacy of disease diagnosis. This work was under-
taken by the patient’s care team, and looked only at bacteria in blood samples. It did not
involve the analysis or study of relevant material as defined by the Human Tissue Authority
and so ethical approval was not required. This is in accordance with the revised guidance in
the Governance Arrangements for Research Ethics Committees (GAfREC) that was released
in September 2011 and was found to be fully compliant the NHS Research Governance
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Framework for Health and Social Care (April 2005), and with all other current regulatory
requirements.
Results
A total of 115 patient cases were included in this study. The most common day one Gram
stain finding was Gram positive cocci resembling Staphylococci (49/115), followed by Gram
negative rods (32/115) (Table 1).
Comparison of culture identification with direct MALDI-ToF identification
Of the 115 cases included, 108 (93.9%) achieved identification of one or more isolates from
blood through routine culture and 73 (63.5%) had a pathogen identified with the direct MAL-
DI-ToF identification technique on day one. Of those with a direct identification, 70/73
(95.9%) had a result concordant with the culture result. Three cases had a direct identification
that was discordant with the culture result. The discordant results are shown in Table 2.
Of the 28 cases from which a single Gram negative organism was identified by culture, 26
(89%) had the Gram negative organism identified by MALDI-ToF. Of the 60 cases from which
a single Gram positive organism was identified by culture, 32 (53%) had the Gram positive
organism identified by MALDI-ToF.
Overall clinical impact
In 28 of the 115 included cases, early MALDI-ToF identification would have had clinical bene-
fit. When determining the impact of early organism identification each clinical impact cate-
gory was considered separately. As a result some cases fell into more than one category, for
example an early identification may have provided information of source of infection and
informed antimicrobial agent choice. The results for each clinical impact category is reported
below.
Table 1. Results of positive blood culture Gram stains on day one.
Gram Stain Result Cases (%)
Staphylococci 49 (43)
Gram Negative Rods 32 (28)
Streptococci 15 (13)
Gram Positive Rods 10 (8)
Mixed Gram Stain 7 (6)
Gram Negative Cocci 1 (<1)
Haemolysed Bottle 1 (<1)
doi:10.1371/journal.pone.0169332.t001
Table 2. Discordant results of conventional culture vs. direct MALDI-ToF identification.
Organisms seen in direct blood culture Gram
stain
Organisms identified from growth plate sub-culture Organisms identified by direct
MALDI-ToF
Streptococcus and Yeast Candida albicans and Granulicatella Staphylococcus epidermidis
Staphylococcus and Streptococcus Enterococcus faecalis and Mixed coagulase negative
staphylococci
Staphylococcus haemolyticus
Streptococcus Mixed coagulase negative staphylococci and Gram positive
rod
Granulicatella adiacens
doi:10.1371/journal.pone.0169332.t002
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Determining clinical significance of a positive blood culture
Of the 115 patient cases, 102 episodes of communication between an infection specialist and
the primary clinical team were made on day one of the blood culture result. This consisted of a
bedside review or telephone consultation where the Gram stain result was relayed, as well as
advice regarding investigation, source control, antimicrobial chemotherapy and infection con-
trol measures where appropriate. On the basis of clinical judgement, 11 Gram stain results
were not communicated to clinical teams on day one. In addition, two patients had died before
the blood culture result was available and therefore the result was not conveyed to a clinical
team. With the benefit of direct MALDI-ToF identification, a total of 14 additional cases
(12%), all coagulase negative staphylococci, could have had the blood culture growth desig-
nated as ‘of doubtful clinical significance’ on day one. This would have avoided 14 episodes of
communication with clinical teams that did not influence patient care.
Identifying the source of infection and making recommendations for
investigation
Direct MALDI-ToF identification on day one would have indicated a different source of infec-
tion or changed the advice regarding investigation of the patient in 11 out of 115 cases (9.6%).
Ten of these involved a Gram positive organism (3 cases Staphylococcus aureus, 2 cases Entero-
coccus faecalis, and one case of each of the following organisms; Streptococcus pneumoniae,
Staphylococcus hominis, Micrococcus luteus, Streptococcus sanguinis). The only case including a
Gram negative organism involved a blood culture with a day one Gram of Gram positive cocci
resembling Staphylococci which cultured only an Escherichia coli. The direct MALDI-ToF
method correctly identified this blood culture as containing E. coli on day one.
Selection of antimicrobial agents
In 11 cases (9.6%), the MALDI-ToF identification of an organism on day one would have been
an indication for changing the antimicrobial agent selected on the basis of the Gram stain
result. In the nine cases where a Gram positive organism was isolated, five of the patients
could have received more narrow-spectrum antimicrobial therapy from day one (Table 3). In
the two Gram negative bacteraemia cases, one patient could have received more narrow-
Table 3. Summary of antimicrobial changes made with organism identification.
Organisms seen in direct blood culture
Gram stain day one (number of bottles
positive)
Antibiotics
recommended on day
one
Organisms identified by
direct MALDI-ToF on day
one
Organisms identified from
growth on plate sub-culture
day two
Antibiotic change
on day two
Staphylococcus (2/2) Vancomycin S. aureus S. aureus Flucloxacillin
Streptococcus (2/2) Nil E. faecalis E. faecalis Amoxicillin
Gram negative rod (1/2) Meropenem Klebsiella pneumoniae K. pneumoniae Ertapenem
Streptococcus (2/2) Co-amoxiclav S. pneumoniae S. pneumoniae & S. capitis Benzylpenicillin
Staphylococcus (1/2) Flucloxacillin M. luteus M. luteus Vancomycin
Streptococcus (2/2) Ertapenem E. faecium E. faecium Ertapenem and
vancomycin
Streptococcus (2/2) Meropenem E. faecium E. faecium Meropenem and
vancomycin
Gram negative rod (2/2) Tazocin E. cloacae E. cloacae Meropenem
Staphylococcus (2/2) Tazocin S. aureus S. aureus Flucloxacillin
Streptococcus (2/2) Amoxicillin S. sanguinis S. sanguinis Benzylpenicillin
Staphylococcus (2/2) Vancomycin S. aureus S. aureus Flucloxacillin
doi:10.1371/journal.pone.0169332.t003
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spectrum antibiotics from day one. Knowing the identification of an organism on day one
would have facilitated five patients receiving appropriate antibiotics 24 hours sooner in their
illness (highlighted in bold in Table 3).
Infection prevention and control
No cases had the potential for an earlier infection control intervention as a result of the direct
MALDI-ToF identification. During the data collection period there was one case of Streptococ-
cus pyogenes bacteraemia. In this particular patient, S. pyogenes had already been isolated from
a knee aspirate and appropriate infection control measures were already in place. As such,
there was no indication for any additional infection control intervention in response to the
identification of the blood culture isolate.
Discussion
Results from our study demonstrate that direct identification of organisms in positive blood
culture bottles using MALDI-ToF can have a clinical impact in patients with bacteraemia. Day
one identification of organisms from positive blood cultures, particularly Staphylococcal spe-
cies, assists the infection specialist in assessing the clinical significance of a blood culture iso-
late, allows streamlining of clinical services, and prioritisation of cases where consultation is
most likely to impact on patient care. As Martiny et al [7] highlighted, this is likely to be of par-
ticular help in the paediatric setting where the blood culture contamination rate is high. There
is also potential for patients to avoid unnecessary exposure to antimicrobials if clinicians can
be assured of the identification of a blood culture isolate. In both respects, use of MALDI-ToF
for day one identification can be considered a service quality improvement, the impact of
which is experienced by both the infection specialist and the wider hospital community.
Accurately identifying the source of infection is a key component in determining how to
manage a patient with bacteraemia. MALDI-ToF identification of a Gram positive organism
helps to narrow down the potential source of infection and provide a focus for clinical investi-
gation from day one. Our results suggest this is most often the case for species that appear as
Streptococci in a Gram stain, for example the identification of E. faecalis would prompt abdom-
inal investigations. Equally, establishing that an organism is likely to be a contaminant would
allow the infection specialist to confidently forgo further investigation that may be under con-
sideration, for example ruling out a S. aureus bacteraemia on day one would avoid unnecessary
additional imaging and repeat blood cultures. Whilst the benefit of organism identification is
apparent for Gram positive organisms, for cases of Gram negative bacteraemia early organism
identification is less likely to contribute to source identification or investigation.
Even in the absence of susceptibility testing, organism identification can directly influence
the choice of antimicrobial agent. These results concur with a published study by Vlek et al
[11] who also demonstrated MALDI-ToF identification improves appropriateness of antibiotic
therapy 24 hours after blood culture positivity. From our results, two scenarios can be charac-
terised: 1) The organism identification is that of a common pathogen with a somewhat predict-
able susceptibility profile. This allows narrow spectrum antibiotics to be advised from day one
e.g. Streptococcus pneumoniae. 2) The organism identification is that of a less common patho-
gen suggesting antibiotics with a broader spectrum of activity are required from day one than
would typically be given on the Gram stain result alone e.g. Enterobacter cloacae. By facilitating
the use of more narrow-spectrum antibiotics, the direct MALDI-ToF method can be viewed as
contributing positively to antimicrobial stewardship. When considering cases where broader-
spectrum antibiotics are indicated, organism identification allows earlier appropriate antimi-
crobial therapy, which may otherwise be delayed. A similar impact was documented by Clerc
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et al [10] who described MALDI-ToF identification altering antibiotic management in 59.3%
of bacteraemias caused by AmpC-producing Enterobacteriaceae. Results from our study have
demonstrated a potential impact on prescribing that can benefit the individual patient and the
wider patient population within a healthcare organisation.
For commonly encountered Gram negatives with a highly variable susceptibility profile,
such as E. coli, organism identification alone is less helpful for informing antimicrobial agent
choice. However, advances in the use of MALDI-ToF for generating susceptibility profiles [12–
14] suggests that utilisation of the mass spectrometry technology is only set to increase. Rapid
detection of organisms with highly resistant susceptibility profiles, such as carbapenemase pro-
ducing enterobacteriaceae (CPE), would not only facilitate more appropriate antimicrobial
choice but also give MALDI-ToF a vital role in hospital based infection prevention and control.
Most indications for infection control interventions, such as patient isolation, are dependent
upon the antimicrobial susceptibility profile of an organism. If use of direct MALDI-ToF iden-
tification can provide this information, earlier implementation of heightened infection control
measures will reduce the risk of transmission of these organisms. This would be a valuable tool
in the on-going effort to keep our patients safe from healthcare associated infections.
Use of direct MALDI-ToF identification has significant potential, however limitations must
also be acknowledged. The proportion of positive blood culture bottles that will not generate a
reliable identification limits the clinical impact of direct MALDI-ToF use. In our study we
demonstrated a successful MALDI-ToF identification in 53% of cases with single Gram posi-
tive organisms, significantly lower than the identification rate of Gram negative organisms
(89%). This is consistent with a number of previously published studies that found a signifi-
cantly better rate of acceptable identification result in Gram negative organisms [3,4,15]. As
cases of Gram positive bacteraemia are the scenario in which day one identification currently
has the greatest potential benefit, the rate of reliable identification in this group is critical.
Our study design, through necessity, did not allow clinical decision-making as a result of
direct MALDI-ToF results. As a result, significant clinical outcomes such as patient mortality
and length of stay could not be measured. Instead, potential clinical impacts were assessed as
outcomes measures and the authors acknowledge this as a limitation of our study. For this rea-
son, further prospective investigation of the clinical impact of using direct MALDI-ToF identi-
fication is warranted and would contribute further to the body of evidence on this topic.
In addition to using MALDI-ToF to generate susceptibility profiles, expanding the type of
clinical specimen that can be analysed by mass spectrometry presents opportunities for new
diagnostic pathways. MALDI-ToF has been rapidly adopted by hospital-based laboratories, in
part due to its ease of use and contribution to improved laboratory workflow. The expanded
use of MALDI-ToF has huge potential and few barriers in terms of additional training or
demands on laboratory time. As this technology evolves to accurately identify a broader range
of organisms and resistance mechanisms, the clinical impact of MALDI-ToF on diagnosis,
antimicrobial stewardship and infection control will surely increase.
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